Text Search: Search by:

Refine your search with filters

Year:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

P297: Ulcerative colitis and proximal extension of the disease: a sub-group with worse prognosis?ECCO '16 Amsterdam

Year: 2016

Authors:

P. Sousa*, D. Martins, J. Pinho, R. Araújo, E. Cancela, A. Castanheira, P. Ministro, A. Silva

Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal

P298: Comparison of the familial and sporadic cases of inflammatory bowel diseases in long-term follow-up regarding step-up treatment, clinical, and biochemical parametersECCO '16 Amsterdam

Year: 2016

Authors:

S. Bozcan*, I. Hatemi, Y. Erzin, G. Ayan, A. Satman, T. Gundogdu, K. Atay, N. Demir, A.F. Celik

Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey

P299: Is quality of life different between Crohn’s disease patients submitted to early surgery or immunosuppression?ECCO '16 Amsterdam

Year: 2016

Authors:

R. Barosa*, M. Patita, G. Nunes, C. Carreira, C. Cruz, C. Boal, A. I. Vieira, J. Freitas

Hospital Garcia de Orta, Gastroenterology, Almada, Portugal

P300: Predictors of a second surgery in patients with Crohn’s disease: are we following the right path?ECCO '16 Amsterdam

Year: 2016

Authors:

S. Raimundo Fernandes*, S. Bernardo, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, L. Correia, J. Velosa

Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

P301: Gender influencing attitudes to inflammatory bowel disease: a questionnaire investigating the effect of IBD on body-image, sexual function, and family planningECCO '16 Amsterdam

Year: 2016

Authors:

K. Boland*, M. Forry, N. Godwin, E. Tatro, F. E. Murray, G. C. Harewood, S. Patchett, A. O Toole

Beaumont Hospital, Department of Gastroenterology and Hepatology, Dublin, Ireland

P302: Faecal calprotectin correlates with small bowel inflammatory activity detected by capsule endoscopy in patients with established Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

M. Barbosa*¹, S. Monteiro¹, T. Gonçalves¹, M. J. Moreira¹, B. Rosa¹, J. Cotter^{1, 2, 3}

¹Hospital da Senhora da Oliveira, Gastroenterology, Guimaraes, Portugal, ²Instituto de Investigação em Ciências da Vida e da Saúde, Universidade do Minho, Braga, Portugal, ³Laboratório Associado ICVS/3B´s, Braga, Portugal

P303: Factors associated with the development of extraintestinal manifestations in patients with ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

J. Yamamoto-Furusho*¹, G. Sanchez-Morales²

¹IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico

P304: Patients with perianal Crohn’s disease have poor disease outcomes after primary bowel resectionECCO '16 Amsterdam

Year: 2016

Authors:

Y. M. Han*¹, J. W. Kim², J. H. Kim¹, S.-J. Koh², H. Yoon³, C. Lee⁴, J. P. Im¹, J. S. Kim¹

¹Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, ²Seoul National University Boramae Hospital, Department of Internal Medicine, Seoul, South Korea, ³Seoul National University Bundang Hospital, Departments of Internal Medicine, Seongnam, South Korea, ⁴Healthcare System Gangnam Centre, Seoul National University Hospital, Department of Internal Medicine, Division of Gastroenterology, Seoul, South Korea

P305: No increased risk for infections with thiopurine-induced leukopenia in inflammatory bowel disease patients without a variant in thiopurine S-methyltransferaseECCO '16 Amsterdam

Year: 2016

Authors:

M. Broekman*¹, M. Coenen², C. van Marrewijk², G. Wanten¹, L. Derijks³, S. Vermeulen^{2, 4}, D. Wong⁵, O. Klungel⁶, A. Verbeek⁴, P. Hooymans⁵, H. Scheffer², H.-J. Guchelaar⁷, D. de Jong¹

¹Radboud University Medical Centre, Department of Gastroenterology, Nijmegen, Netherlands, ²Radboud University Medical Centre, Department of Human Genetics, Nijmegen, Netherlands, ³Maxima Medical Centre Loc. Veldhoven, Department of Gastroenterology and Hepatology, Veldhoven, Netherlands, ⁴Radboud University Medical Centre, Radboud Institute for Health Sciences, Nijmegen, Netherlands, ⁵Zuyderland Medical Centre, Department of Clinical Pharmacy, Pharmacology and Toxicology, Sittard, Netherlands, ⁶Utrecht University, Departement of Pharmacoepidemiology and Clinical Pharmacotherapy, Utrecht, Netherlands, ⁷Leiden University Medical Centre, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands

P306: The real-life experience of vedolizumab efficacy and safety in ulcerative colitis: a prospective observational multicentre cohort studyECCO '16 Amsterdam

Year: 2016

Authors:

A. Amiot*¹, L. Peyrin-Biroulet², C. Stefanescu³, J. C. Grimaud⁴, J. Filippi⁵, B. Pariente⁶, X. Roblin⁷, R. Altwegg⁸, D. Laharie⁹, P. Marteau¹⁰, A. Buisson¹¹, C. Trang-Poisson¹², S. Nancey¹³, G. Savoye¹⁴, S. Viennot¹⁵, H. Brixi-Benmansour¹⁶, F. Carbonnel¹⁷, Y. Bouhnik³

¹Henri Mondor Hospital, Gastroenterology, Creteil, France, ²CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, ³APHP Beaujon, Department of Gastroenterology, Clichy, France, ⁴Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, ⁵Archet 2 Hospital, Department of Gastroenterology, Nice, France, ⁶CHRU Lille, Department of Gastroenterology, Lille, France, ⁷University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, ⁸CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, ⁹CHU Bordeaux, Department of Gastroenterology, Bordeaux, France, ¹⁰Hospital Lariboisière, Department of Gastroenterology, Paris, France, ¹¹CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, ¹²CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, ¹³Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, ¹⁴CHU Rouen, Department of Gastroenterology, Rouen, France, ¹⁵Hospital Cote de Nacre, Department of Gastroenterology, Caen Cede, France, ¹⁶Robert Debre Hospital, Department of Gastroenterology, Reims, France, ¹⁷CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France

P307: Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extensionECCO '16 Amsterdam

Year: 2016

Authors:

W. Reinisch*¹, P. Gibson², W. J. Sandborn³, B. Feagan⁴, C. Marano⁵, R. Strauss⁵, J. Johanns⁵, H. Zhang⁵, L. Padgett⁵, O. J. Adedokun⁵, J.-F. Colombel⁶, J. Collins⁷, P. Rutgeerts⁸, D. Tarabar⁹

¹Universitätsklinik für Innere Medizin III and McMaster University, Vienna and Hamilton, Austria, ²Alfred Hospital, Melbourne, Australia, ³University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, ⁴Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, ⁵Janssen R & D, LLC, Spring House, Pennsylvania, United States, ⁶Mount Sinai, Icahn School of Medicine, New York, New York, United States, ⁷Oregon Health Sciences University, Department of Gastroenterology, Portland, Oregon, United States, ⁸University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, ⁹Military Medical Academy, Department of Gastroenterology and Hepatology, Belgrade, Serbia

P308: Predictors of loss of response to adalimumab therapy: the importance of therapeutic drug monitoring in inflammatory bowel diseasesECCO '16 Amsterdam

Year: 2016

Authors:

Z. Kurti*¹, Z. Vegh¹, M. Rutka², L. Gonczi¹, K. Farkas², K. Gecse¹, P. A. Golovics¹, B. Szalay³, T. Molnar², P. Lakatos¹

¹Semmelweis University, First Department of Medicine, Budapest, Hungary, ²University of Szeged, First Department of Medicine, Szeged, Hungary, ³Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

P309: High infliximab trough levels are associated with better control of inflammation in inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

D. Drobne*¹, T. Kurent¹, P. Rajar², M. Slak³, M. Kozelj¹, G. Novak¹, N. Smrekar¹, S. Plut¹, A. Smid¹, J. Osredkar⁴, B. Stabuc¹, I. Ferkolj¹

¹University Medical Centre Ljubljana, Department of Gastroenterology and Hepatology, Ljubljana, Slovenia, ²University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, ³Faculty of Pharmacy, Ljubljana, Slovenia, ⁴University Medical Centre Ljubljana, Clinical Institute of clinical chemistry and biochemistry, Ljubljana, Slovenia

P310: Patient-reported quality of life during golimumab induction for moderate-to-severe ulcerative colitis in the United Kingdom: results from the GO-COLITIS studyECCO '16 Amsterdam

Year: 2016

Authors:

P. Irving*¹, C. Probert², D. R. Gaya³, P. J. Hamlin⁴, S. Sebastian⁵, G. Gillespie⁶, H. Tate⁶, C. Wheeler⁶

¹Guy’s and St Thomas’ Hospitals, London, United Kingdom, ²University of Liverpool, Liverpool, United Kingdom, ³Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁴Leeds Teaching Hospitals Trust, Leeds, United Kingdom, ⁵Hull & East Yorkshire NHS Trust, Hull, United Kingdom, ⁶MSD UK, Hoddesdon, United Kingdom

P311: No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term resultsECCO '16 Amsterdam

Year: 2016

Authors:

K. Malickova¹, D. Duricova*², M. Kolar², M. Bortlik², V. Hruba², N. Machkova², K. Mitrova², M. Lukas Jr.², M. Lukas²

¹First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, ²ISCARE, IBD clinical and research centre, Prague, Czech Republic

P312: Has IBD specialists’ awareness of biosimilar monoclonal antibodies changed? Results from a survey amongst ECCO membersECCO '16 Amsterdam

Year: 2016

Authors:

S. Danese*^{1, 2}, G. Fiorino¹, P. Michetti³

¹Humanitas Research Hospital, IBD Centre, Gastroenterology, Rozzano, Milan, Italy, ²Humanitas University, Biomedical Sciences, Rozzano, Milan, Italy, ³Clinique La Source-Beaulieu, Crohn and Colitis Centre, Lausanne, Switzerland

P313: Comparison of accelerated infliximab induction versus standard induction treatment in acute severe ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

M. Choy*^{1, 2, 3}, D. Seah^{1, 3}, A. Gorelik⁴, F. Macrae⁵, M. Sparrow⁶, W. R. Connell², G. Moore⁷, D. Van Langenberg⁸, P. De Cruz^{1, 3}

¹Austin Health, Department of Gastroenterology, Melbourne, Australia, ²St Vincent’s Hospital, Department of Gastroenterology, Melbourne, Australia, ³University of Melbourne, Department of Medicine, Melbourne, Australia, ⁴Royal Melbourne Hospital, Melbourne EpiCentre, Melbourne, Australia, ⁵Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia, ⁶The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia, ⁷Monash Health, Department of Gastroenterology, Melbourne, Australia, ⁸Eastern Health, Department of Gastroenterology, Melbourne, Australia

P314: Proposal for an anti-tumour necrosis factor–exit strategy based on trough serum levelECCO '16 Amsterdam

Year: 2016

Authors:

U. Helwig*¹, F. Lutter¹, N. Koppka², S. Schreiber³

¹University of Kiel, Medical Practice for Internal Medicine, Oldenburg, Germany, ²Medical Practice for Internal Medicine, Oldenburg, Germany, ³Department of Internal Medicine I - Gastroenterology, Hepatology, Nutrition and Geriatric Medicine, University Hospital Schleswig-Holstein, campus Kiel, Kiel, Germany

P315: Effect of age on beliefs about and adherence to medications in patients with inflammatory bowel disease: results from the ALIGN studyECCO '16 Amsterdam

Year: 2016

Authors:

P. Michetti*¹, L. Peyrin-Biroulet², M. S. Silverberg³, E. Louis⁴, J. Weinman⁵, J. Sommer⁶, J. Petersson⁷, B. Pappalardo⁷, P. Nurwakagari⁸

¹IBD Centre La Source-Beaulieu, Lausanne, Switzerland, ²Inserm U954 and Department of Gastroenterology, Université de Lorraine, Vandoeuvre-les-Nancy, France, ³Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁴CHU de Liège et Université de Liège, Liège, Belgium, ⁵Institute of Pharmaceutical Sciences & Institute of Psychiatry, King’s College, London, United Kingdom, ⁶GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁷AbbVie Inc., North Chicago, Illinois, United States, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany

P316: Prognosis of patients with inflammatory bowel disease in clinical remission after de-escalation of infliximab maintenance therapy from 8 to 12 weeksECCO '16 Amsterdam

Year: 2016

Authors:

J. M. Vázquez-Morón, B. Benítez-Rodríguez*, H. Pallarés-Manrique, M. Ramos-Lora

Hospital General Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain